BEGIN:VCALENDAR PRODID:-//github.com/rianjs/ical.net//NONSGML ical.net 4.0//EN VERSION:2.0 BEGIN:VEVENT DESCRIPTION:The Pharma and Biotech Patent Litigation Track at the Patent L itigation Europe Summit 2026 is the leading European forum for life scien ces IP counsel and litigators to benchmark enforcement strategies\, navig ate evolving UPC case law\, and prepare for the next wave of biosimilar a nd generic challenges. Taking place on 20–21 January 2026 at the Beurs va n Berlage in Amsterdam\, the track continues the legacy of the Pharma and Biotech Patent Litigation Summit while introducing a broader cross-secto r environment under the newly rebranded Patent Litigation Europe umbrella .\n\nThis stream remains the anchor event for the life sciences audience\ , attracting around 600 attendees\, with an exceptional 45% in-house coun sel ratio from leading pharmaceutical innovators\, biotechs\, generics an d biosimilar developers. The track will again be hosted in the dedicated Pharma and Biotech conference room\, while sharing networking spaces and sessions with attendees from the Tech and Innovation Patent Litigation tr ack\, enabling delegates to connect across industries and discuss the str ategic overlaps between life sciences\, AI\, and regulatory-driven IP enf orcement.\n\nThe Pharma and Biotech agenda focuses on the issues that def ine market exclusivity and drive litigation across Europe. Topics include : preliminary injunctions\, UPC procedures and case law\, Supplementary P rotection Certificates (SPCs)\, Bolar exemptions\, second medical use cla ims\, and biosimilar launch strategies. The programme explores how compan ies can defend exclusivity\, manage parallel litigation across jurisdicti ons\, and adapt to the unified enforcement landscape emerging under the U nified Patent Court (UPC)\, which now has over 1000 filings and is reshap ing European patent practice.\n\nA central theme of the track is the rela tionship between innovation protection and patient access. Sessions will examine the complex litigation landscape between originators and generics /biosimilars\, assessing how recent UPC and national court decisions impa ct filing strategy\, data protection\, and lifecycle management. Expert c ase studies will explore how litigators balance enforcement with commerci al realities\, providing attendees with practical insights to strengthen internal decision-making and align legal\, regulatory\, and business obje ctives.\n\nThey are joined by senior IP and legal representatives from co mpanies such as Novo Nordisk\, Recordati\, Valneva\, Orion\, Silence Ther apeutics\, Polpharma\, Bruker\, Regeneron\, and Siemens Healthineers\, al ongside leading European patent litigators from Powell Gilbert\, Kirkland and Ellis\, Bardehle Pagenberg\, Potter Clarkson\, and McCarthy Tetrault . This combination ensures both in-house and private practice perspective s are represented at the highest level.\n\nThe track will also include UP C judges\, regulatory experts\, and litigation funders who will share pra ctical insights on how new procedural and evidentiary frameworks are shap ing outcomes across Europe. Delegates will gain clarity on how early UPC judgments are influencing injunction practice\, damages calculations\, an d cross-border enforcement\, and how to prepare effective litigation stra tegies under this new system.\n\nNetworking remains at the core of the ev ent. With a structured 1-2-1 meeting programme\, shared networking spaces \, and curated receptions\, attendees can pre-book targeted meetings with key clients\, prospects\, or peers. This format ensures that law firms\, service providers\, and corporate legal teams maximise the value of thei r attendance through meaningful\, business-driven interactions.\n\nFor li fe sciences companies\, the benefits are clear: the ability to benchmark litigation strategy\, learn directly from UPC decision-makers\, exchange insights with industry peers\, and prepare for future regulatory and mark et developments that directly impact exclusivity and portfolio value. For private practice litigators\, the event provides a concentrated opportun ity to reconnect with clients and demonstrate expertise in handling compl ex\, cross-border disputes across Europe's most active jurisdictions.\n\n Above all\, the Pharma and Biotech Patent Litigation Track is designed to address the key question at the heart of every life sciences company's p atent strategy - how to defend innovation while ensuring commercial succe ss. With its balance of technical\, procedural\, and strategic content\, it provides both depth and practicality\, making it the go-to annual meet ing for professionals shaping the future of European pharmaceutical paten t litigation.\n\nAs part of the wider Patent Litigation Europe Summit\, t his track benefits from the event's broader cross-sector energy\, uniting the life sciences community with peers from the technology\, automotive\ , and telecommunications industries. This integrated approach reflects th e evolving nature of IP law itself\, as AI\, data\, and platform technolo gies increasingly intersect with pharma innovation.\n\nURLs:Tickets:  \;https://go.evvnt.com/3311939-0?pid=185Website: \;https://go.evvnt.c om/3311939-2?pid=185Brochure: \;https://go.evvnt.com/3311939-3?pid=18 5Brochure: \;https://go.evvnt.com/3311939-4?pid=185\n\nPrices:Tier 1 - In-House Counsel: EUR 499.00\,Tier 2 - Law Firm: EUR 1999.00\,Tier 3 - Service Provider: EUR 2999.00\n\nCategory: \;Conferences | Science\, Health and Medicine | Pharmaceuticals\n\nDate and Time: \;19th Januar y 2026 at 9:00 am to 21st January 2026 at 5:00 pm\n\nVenue details: \ ;Beurs van Berlage\, 243 Damrak\, Amsterdam\, Noord-Holland\, 1012 ZJ\, N etherlands\n DTEND:20260121T170000 DTSTAMP:20260512T230903Z DTSTART:20260119T090000 LOCATION:Beurs van Berlage\, 243\, Damrak\, Amsterdam\, Noord-Holland\, 10 12 ZJ\, SEQUENCE:0 SUMMARY:The Pharma and Biotech Patent Litigation Track at the Patent Litig ation Europe Summit 2026 is the leading European forum for life sciences IP couns... UID:6eca01ab-3db6-461d-b0a6-af679009dbef END:VEVENT END:VCALENDAR